Next Article in Journal
Targeted Isolation of Antioxidant Constituents from Plantago asiatica L. and In Vitro Activity Assay
Previous Article in Journal
Atypical Lindenane-Type Sesquiterpenes from Lindera myrrha
Open AccessArticle

Combination Therapy of Acarbose and Cyclosporine a Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice

1
Department of Medical Research, Taichung Veterans General Hospital, Taichung 407, Taiwan
2
Institute of Biomedical Science and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan
3
Department of Medical Research, China Medical University Hospital, Taichung 404, Taiwan
4
Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei 110, Taiwan
5
Nutrition Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan
6
Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, Taipei Medical University, Taipei 110, Taiwan
7
Department of Exercise and Health Science, National Taipei University of Nursing and Health Sciences, Taipei 112, Taiwan
8
Division of Plastic Surgery, Department of Surgery, Cathay General Hospital, Taipei 280, Taiwan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Francesco Maione
Molecules 2020, 25(8), 1822; https://doi.org/10.3390/molecules25081822
Received: 30 March 2020 / Revised: 11 April 2020 / Accepted: 13 April 2020 / Published: 16 April 2020
Moderate to severe psoriasis, an immune-mediated inflammatory disease, adversely affects patients’ lives. Cyclosporin A (CsA), an effective immunomodulator, is used to treat psoriasis. CsA is ineffective at low doses and toxic at high doses. Acarbose (Acar), a common antidiabetic drug with anti-inflammatory and immunomodulatory effects, reduces imiquimod (IMQ)-induced psoriasis severity. Combinations of systemic drugs are generally more efficacious and safer than higher doses of single drugs. We observed that mice treated with a combination of Acar (250 mg/kg) and low-dose CsA (10 or 20 mg/kg) exhibited significantly milder IMQ-induced psoriasis-like dermatitis and smoother back skin than those treated with Acar (250 mg/kg), low-dose CsA (10 or 20 mg/kg), or IMQ alone. The combination therapy significantly reduced serum and skin levels of Th17-related cytokines (interleukin (IL)-17A, IL-22, and IL-23) and the Th1-related cytokine tumor necrosis factor-α (TNF-α) compared with Acar, low-dose CsA, and IMQ alone. Additionally, the combination therapy significantly reduced the percentages of IL-17- and IL-22-producing CD4+ T-cells (Th17 and Th22 cells, respectively) and increased that of Treg cells. Our data suggested that Acar and low-dose CsA in combination alleviates psoriatic skin lesions by inhibiting inflammation. The findings provide new insights into the effects of immunomodulatory drugs in psoriasis treatment. View Full-Text
Keywords: acarbose; cyclosporine; psoriasis; imiquimod; combination therapy acarbose; cyclosporine; psoriasis; imiquimod; combination therapy
Show Figures

Figure 1

MDPI and ACS Style

Chen, H.-H.; Lin, C.-C.; Tung, Y.-T.; Chao, Y.-H.; Huang, W.-C.; Lee, P.-Y. Combination Therapy of Acarbose and Cyclosporine a Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice. Molecules 2020, 25, 1822.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop